// App-Quantinova.ai

2383 : Zymogen-Like FXa Is An Effective Pro-Hemostatic To Reverse The Anticoagulant Effects Of Direct FXa Inhibitors

Researchers

Presenter

  • Nabil K Thalji

Principal Investigators

  • Sunita Patel-Hett

  • Reema Jasuja

  • Joachim Fruebis

  • Debra Pittman

  • Rodney M. Camire

Medical Centers

  • Department of Pathology, The Children's Hospital of Philadelphia, Philadelphia, PA

  • Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

Locations

  • United States

Companies

  • Pfizer Inc.

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Non-valvular atrial fibrillation

  • Venous thrombosis

  • Arrhythmia

  • Hemophilia

Biomarkers

  • Tissue factor pathway inhibitor

  • Antithrombin III

Drug/Treatment

  • Prothrombin complex

  • rivaroxaban

  • Hemostatic Solution

  • apixaban

  • Evithrom

  • Warfarin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved